|Description||(-)-Terreic acid is a selective inhibitor of Bruton's tyrosine kinase (BTK) with antibiotic activity. (-)-Terreic acid inhibits the catalytic activity of BTK and suppresses the interaction between PKCbII and BTK (IC50 ~ 30 mM).|
|Brife Description||BTK inhibitor|
|Purity||≥99% by HPLC|
|Synonyms||(1R,6S)-3-Hydroxy-4-methyl-7-oxabicyclo[4.1.0]hept-3-ene-2,5-dione; Terreic Acid; 5,6-Epoxy-3-hydroxy-p-toluquinone|
Btk inhibitor 1 R enantiomer hydrochlori
Btk inhibitor 1R enantiomer Hcl is a pyrazolo[3,4-d]pyrimidine derivative as a <strong>Btk </strong>kinase inhibitor.
RN983 is a selective BTK enzyme inhibitor. It inhibits IgG production in B-cells with an IC50 value of 2.5 ± 0.7 nM and PGD2 production from mast cells with an ...
CGI1746 is a small-molecule Btk inhibitor chemotype with a new binding mode that stabilizes an inactive nonphosphorylated enzyme conformation. CGI1746 has exqui...
Potent BTK inhibitor (IC50 = 0.3 nM). Blocks B cell antigen receptor (BCR)-mediated gene expression in CD20+ B cells.
GDC-0834 is a small molecule inhibitor of Btk potentially useful in the treatment of RA and lymphoid malignancies. Administration of GDC-0834 (30 -- 100 mg/kg)...
Ibrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK). It binds to BTK to suppress both B-cell activation and B-cell-mediated signaling.
BGB-3111 is a potent, selective and orally available Bruton's tyrosine kinase (Btk) inhibitor that demonstrates superior oral bioavailability, achieving higher ...
GDC-0834 is a potent and selective inhibitor of Bruton's tyrosine kinase (BTK), investigated as a potential treatment for rheumatoid arthritis. In vitro metabol...